Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Henry Fisher: Our CMC Invest clients can monitor thematic watchlists, featuring curated lists of shares across 22+ themes.

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost ...

* Computed on last 15 days' trading figures.

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Pfizer (NYSE:PFE) with a Market Perform ...

The major U.S. stock market indexes are officially in overheated territory thanks to enthusiasm for artificial intelligence ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The stock's rise snapped a three-day losing streak.